Zomedica Corp. [AMEX: ZOM] stock went on a downward path that fall over -1.08% on Tuesday, amounting to a one-week price decrease of less than -2.38%. The company report on November 14, 2022 that Zomedica Announces Third Quarter 2022 Financial Results: $4.78 Million Revenue; 75% Gross Margin & $158.49 Million in Cash, Cash Equivalents, and Available-For-Sale Securities.
Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”, a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, reported consolidated financial results for the three- and nine-month periods ended September 30, 2022. Amounts are presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Larry Heaton, Zomedica’s Chief Executive Officer, commented: “During the third quarter of 2022 we both grew revenue organically, and also closed on several acquisitions. We were pleased with our revenue growth to $4.78 million, which reflects an approximate 24% increase in the sales of our pre-existing PulseVet® and TRUFORMA® products over 2021 levels; and a 17% increase, on a pro-forma basis, over the combined revenue of Zomedica, Pulse Veterinary Technologies (“PulseVet”), and Assisi Animal Health (“Assisi”) as standalone companies, of $4.10 million from the same period in 2021.
Over the last 12 months, ZOM stock dropped by -52.17%. The average equity rating for ZOM stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $197.85 million, with 979.95 million shares outstanding and 965.42 million shares in the current float. Compared to the average trading volume of 7.39M shares, ZOM stock reached a trading volume of 4162821 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Zomedica Corp. [ZOM]:
The Average True Range (ATR) for Zomedica Corp. is set at 0.01, with the Price to Sales ratio for ZOM stock in the period of the last 12 months amounting to 11.71. The Price to Book ratio for the last quarter was 0.74, with the Price to Cash per share for the same quarter was set at 0.12.
ZOM Stock Performance Analysis:
Zomedica Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.38. With this latest performance, ZOM shares dropped by -10.11% in over the last four-week period, additionally sinking by -14.11% over the last 6 months – not to mention a drop of -52.17% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 37.79, with the RSI for the last a single of trading hit 32.19, and the three-weeks RSI is set at 40.87 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.2171, while it was recorded at 0.2040 for the last single week of trading, and 0.2639 for the last 200 days.
Insight into Zomedica Corp. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Zomedica Corp. [ZOM] shares currently have an operating margin of -517.14 and a Gross Margin at +46.32. Zomedica Corp.’s Net Margin is presently recorded at -444.78.
Return on Equity for this stock declined to -11.01, with Return on Assets sitting at -10.61.
Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.50 and a Current Ratio set at 17.80.
Zomedica Corp. [ZOM] Insider Position Details
There are presently around $19 million, or 9.70% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 46,329,005, which is approximately 5.111% of the company’s market cap and around 1.48% of the total institutional ownership; BLACKROCK INC., holding 11,320,780 shares of the stock with an approximate value of $2.27 million in ZOM stocks shares; and CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC., currently with $2.25 million in ZOM stock with ownership of nearly 0.179% of the company’s market capitalization.
Positions in Zomedica Corp. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 25 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 3,349,305 shares. Additionally, 34 investors decreased positions by around 5,531,699 shares, while 42 investors held positions by with 83,513,606 shares. The mentioned changes placed institutional holdings at 92,394,610 shares, according to the latest SEC report filing. ZOM stock had 9 new institutional investments in for a total of 500,622 shares, while 16 institutional investors sold positions of 1,776,674 shares during the same period.